anonymous
Guest
anonymous
Guest
Taltz is doing horribly. Probably one of the absolute worst launches of any biologics used for psoriasis. The definition of a "me too" following the successful launch of Cosentyx. Higher rates of immunogenicity compared to Cosentyx. Higher rates of injection site reaction. Same efficacy. Doesn't add anything different or more valuable to dermatologists or to patients. It was literally a race of who will launch first: Novartis or Lilly. And Novartis won that race. I know dermatologists who literally told me they throw anything they get about Taltz in the main straight in the garbage.